Two Peaks in MIS-C Followed COVID-19 Peaks in the US
Lowest proportion of severe manifestations seen in patients aged 0 to 4 years, but 44.3 percent admitted for intensive care
Emerging Diseases
Type O and Rh-Negative Blood Type Protective Against COVID-19
Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
ACR Guidelines for the Management of Pediatric Multisystem Inflammatory Syndrome Associated With SARS-CoV-2
The American College of Rheumatology developed guidance for the management of pediatric patients with multisystem inflammatory syndrome associated with COVID-19.
Early Data Show Investigational ChAdOx1 nCoV-19 Vaccine Safe, Immunogenic
Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.
More Longitudinal Data Needed to Determine Seasonality of SARS-CoV-2
Researchers explored the question of the seasonality of SARS-CoV-2 by reviewing evidence related to viral viability, transmission, ecological patterns, and observed epidemiology of COVID-19 in the Southern Hemispheres’ summer and early fall.
NIH: New Network Aims to Enroll Thousands for COVID-19 Vaccine, Therapeutics Trials
The COVPN is part of “Operation Warp Speed”, a partnership led by the Department of Health and Human Services (HHS) to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
US Trial Investigating Sarilumab for COVID-19 Stopped
A phase 3 trial evaluating sarilumab (Sanofi and Regeneron), an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.
Siltuximab to Be Evaluated for COVID-19 Associated ARDS in Phase 3 Trial
Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.
Pfizer, BioNTech’s COVID-19 Vaccine Candidate Looks Promising in Early Human Trial
Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.
